Practical guidance diabetes management - introductory talk 
(speaker to be confirmed)

Practical guidance diabetes management - introductory talk 
(speaker to be confirmed)

22 November

08:30Registration & walk-in coffee
09:00Workshop opening
 Session 1: Natural history and epidemiology
09:10Colombo, Massimo 2011Natural history of NASH
Massimo Colombo, MD
Humanitas Research Hospital, Rozzano, Italy

Razavi, Homie 2017 120NASH epidemiology
Homie Razavi, PhD
Center for Disease Analysis (CDA), Louisville, CO, USA

09:50Gender neutral avatar 120x160NASH diagnosis and management in general practice
Winyates Health Centre, United Kingdom
10:10Panel Discussion
10:45Coffee break
 Session 2: Clinical management of NASH - obesity and diabetes management
11:15Practical guidance obesity management - introductory talk 
(speaker to be confirmed)
11:35Clinical case discussion
 11:55Practical guidance diabetes management - introductory talk 
(speaker to be confirmed)
12:15Clinical case discussion
12:35Lunch & Poster viewing
 Session 3: Clinical Management of NASH - Special Populations
13:45Gender neutral avatar 120x160Management of lean NASH
Javier Ampuero, MD, PhD
Hospital Universitario Virgen del Rocío, Seville, Spain

Baker, Alastair 2019Pediatric NAFLD 
Alastair Baker, MB, ChB, FRCP, FRCPCH, MBA
King's College Hospital NHS Foundation Trust, United Kingdom


Gender neutral avatar 120x160NASH in HIV
Berend van Welzen, MD
UMC Utrecht, the Netherlands

14:45 Coffee break
 Session 4: NASH Management

Manuel Romero-Gomez, MDUniversity of Seville, Spain

New biomarkers in NAFLD
Manuel Romero - Gomez, MD
University of Seville, Spain

15:35Zelber-Sagi Shira, 2018How to implement a healthy lifestyle in NAFLD/NASH patients
Shira Zelber-Sagi, PhD
Tel Aviv Sourasky Medical Center, Israel
16:55Roundtable Discussion: The interface of primary and secondary care
Moderator: Emmanouil Tsochatzis, MD, PhD, Royal Free Hospital, United Kingdom
16:30Open Poster Session & Welcome Reception
19:30Workshop Dinner

23 November

 Session 5: NASH and comorbidities
09:00Gender neutral avatar 120x160NASH/NAFLD as cause for HCC
Helen Reeves, MD, PhD
Newcastle Universtity, United Kingdom
09:20Gender neutral avatar 120x160Drug-induced liver injury and NASH
Raúl Andrade, ND, PhD
University Hospital Virgen de la Victoria, Malaga, Spain
09:40Schattenberg,Joern 2018Cardiovascular risk in NAFLD
Jörn M. Schattenberg, MD
Johannes Gutenberg-Universität Mainz, Germany
10:00Gender neutral avatar 120x160NASH and immune-mediated diseases
Maria Teresa Arias-Loste, MD
Hospital Universitario Marques de Valdecilla, Santander, Spain
10:00Roundtable discussion: Current guidelines - still relevant or in need for review?
10:30Coffee break
 Session 6: NASH drug development
11:00What's in the pipeline? Industry presentations
 Session 7: Future treatment and management options

Vlad Ratziu, MD, PhDUniversity of Pierre and Marie Curie, Paris, France

Invited Lecture
Vlad Ratziu, MD, PhD 
Pierre and Marie Curie University, Paris, France

13:20Patient perspective
(speaker to be confirmed)
13:40Roundtable discussion: Current challenges and future trends
14:30Closing remarks
14:40Closure of the Workshop